The purpose of this study is to evaluate the safety and performance of DTXO App in improving weight loss and weight-loss maintenance in obese patients exposed to an experimental non-pharmacological treatment program. The App will include a dietary plan and customized advice program, a customized physical exercise program plan, a cognitive- behavioral assessment and support program, alerts and reminders on prescribed drugs intake and on dietary and exercise program, chat and online visits with clinical professionals, and trophies to improve patient engagement.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Participants must be between 18 and 65 years of age, at the time of signing the informed consent.
* Male and Female.
* Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.
* BMI between 30.0 kg/m2 and 45 kg/m2 .
* Participants must own a mobile phone, be willing to use mobile Apps and this type of technology (technology-savvy) and download the App described in the protocol.
* Native speakers of Italian language or foreign subjects who have a full understanding of the Italian language, as the instructions and information for all health programs will only be given in Italian.
Exclusion Criteria:
* Heart failure (class \>II), ischemic attack or stroke within the previous 6 months to the planned date of randomization.
* History or current evidence of drug or alcohol abuse.
* Chronic kidney failure with GFR category \>G2 (ml/min/1.73 m2).
* Type 1 diabetes.
* Previous malignancy within the first 5 years.
* Active eating disorder or previous history of bulimia and anorexia nervosa, active severe binge-eating disorder.
* Psychiatric disorders not compensated or at risk of decompensation.
* Visual or vision impairments
* Secondary obesity related to endocrinopathies, genetic syndromes, hypothalamic lesions or neurological diseases and immobility.
* Concomitant advanced obesity disease.
* History of bariatric surgery in the previous 2 years or pl…